719 — Shandong Xinhua Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMid CapContrarian

Market Cap
HK$3.72bn
Enterprise Value
HK$5.14bn
Revenue
CNY8.10bn

Annual income statement for Shandong Xinhua Pharmaceutical Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	R2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	CAS	CAS	CAS	CAS	CAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	5,606	6,006	6,560	7,503	8,101
Cost of Revenue
Gross Profit	1,796	1,768	1,740	1,994	2,328
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	5,220	5,588	6,136	7,029	7,571
Operating Profit	386	418	424	474	530
Other Net Non Operating Costs
Net Income Before Taxes	381	412	421	472	533
Provision for Income Taxes
Net Income After Taxes	323	347	362	426	506
Minority Interest
Net Income Before Extraordinary Items
Net Income	300	325	349	411	497
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	300	325	349	411	497
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.489	0.532	0.563	0.625	0.729
Dividends per Share